Immix Biopharma (NASDAQ: IMMX) prices $150M common stock sale
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Immix Biopharma, Inc. is raising capital through an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share, for expected gross proceeds of $150 million and estimated net proceeds of about $140.65 million. The deal is being led by Morgan Stanley under an existing shelf registration statement and is expected to close around May 22, 2026, subject to customary conditions. Immix plans to use the cash mainly to fund development of its BCMA-targeted CAR-T therapy NXC-201, as well as for working capital and general corporate purposes, and believes this financing, together with existing cash, will fund operations into mid-2028.
Positive
- None.
Negative
- None.
Insights
$150M equity raise strengthens cash runway but adds dilution.
Immix Biopharma priced an underwritten offering of 16,778,524 common shares at $8.94, for expected gross proceeds of $150 million and net proceeds of about $140.65 million. This is a primary issuance, so all proceeds go to the company.
The company intends to fund development of its BCMA-targeted CAR-T NXC-201, along with working capital and general corporate needs. Management states that, combined with existing cash, this raise should support operations into mid-2028, which materially extends the disclosed cash runway.
The trade-off for shareholders is equity dilution versus a better-funded clinical plan. Actual impact depends on NXC-201 trial progress and future disclosures in SEC reports about spending pace and additional financing needs.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares offered: 16,778,524 shares
Offering price: $8.94 per share
Gross proceeds: $150 million
+2 more
5 metrics
Shares offered
16,778,524 shares
Underwritten common stock offering
Offering price
$8.94 per share
Public offering price to investors
Gross proceeds
$150 million
Expected gross proceeds from the offering
Net proceeds
$140.65 million
Estimated net after fees and expenses
Cash runway
Into mid-2028
Runway with offering plus existing cash
Key Terms
underwritten offering, shelf registration statement, prospectus supplement, Breakthrough Therapy Designation, +2 more
6 terms
underwritten offering financial
"entered into an underwriting agreement ... in an underwritten offering"
An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.
shelf registration statement regulatory
"The Offering is being made pursuant to a shelf registration statement"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"a prospectus supplement dated May 21, 2026, filed pursuant to Rule 424(b)(5)"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Breakthrough Therapy Designation regulatory
"NXC-201 has been awarded Breakthrough Therapy Designation (BTD)"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
Regenerative Medicine Advanced Therapy regulatory
"Regenerative Medicine Advanced Therapy (RMAT) by the US FDA"
Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene, and tissue‑based therapies intended to treat serious or life‑threatening conditions; it gives developers a “fast lane” with more frequent agency interaction and eligibility for accelerated review pathways. For investors, an RMAT label signals that a therapy may reach market faster and face less regulatory uncertainty than a standard program, which can raise the potential value and reduce timeline risk—though it is not a guarantee of approval.
Orphan Drug Designation regulatory
"Orphan Drug Designation (ODD) by FDA and in the EU by the EMA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
FAQ
What did Immix Biopharma (IMMX) announce in its latest 8-K filing?
Immix Biopharma announced the pricing of an underwritten public offering of 16,778,524 common shares at $8.94 per share. The offering should generate $150 million in gross proceeds, with closing expected around May 22, 2026, subject to customary conditions.
How much money will Immix Biopharma (IMMX) raise from the new stock offering?
Immix Biopharma expects gross proceeds of $150 million from the offering and estimated net proceeds of about $140.65 million. Net proceeds are calculated after underwriting discounts, commissions, and offering expenses, and will go directly to the company as this is a primary issuance.
What will Immix Biopharma (IMMX) use the offering proceeds for?
Immix Biopharma plans to use net proceeds primarily to fund development of its CAR-T candidate NXC-201, along with working capital and general corporate purposes. The company believes the financing plus existing cash will support operations into mid-2028, based on its current plans.
Which banks are managing Immix Biopharma’s (IMMX) $150 million offering?
Morgan Stanley is acting as lead book-running manager and BofA Securities as book-running manager. LifeSci Capital, Mizuho, and Needham & Company are serving as co-lead managers for the underwritten offering of Immix Biopharma’s common stock.
Under which registration statement is Immix Biopharma (IMMX) conducting this offering?
The offering is being conducted under a shelf registration statement on Form S-3, File No. 333-292665. This statement was filed with the SEC on January 9, 2026 and declared effective on January 22, 2026, allowing Immix to issue shares via a prospectus supplement.